secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001937653-26-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks FY2025 revenue up 39% to $106M, net loss down 34%; $250M royalty-backed note from Royalty Pharma
--------------------------------------------------------------------------------

- FY2025 revenue $106.0M (+39% YoY); net loss $81.1M vs $122.7M in 2024.
- Cash & securities $270.6M as of Dec 31; $62.5M used for share repurchases at avg $24.22/share.
- Entered $250M non-recourse royalty-backed note with Royalty Pharma; 70% of Ziihera royalty unencumbered.
- Partner Jazz expects Ziihera sBLA submission in 1Q 2026, potential launch in 2H 2026; up to $440M milestones eligible.
- 2026 adjusted gross opex guided ~20% lower than 2025 adjusted opex of $170.5M, excluding acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765326000013/0001937653-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765326000013/zyme-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001937653-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer